Literature DB >> 27998761

LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2.

Dong Liu1, Yawei Li1, Gang Luo2, Xingyuan Xiao1, Dan Tao3, Xinchao Wu4, Miao Wang1, Chao Huang1, Liang Wang1, Fuqing Zeng5, Guosong Jiang6.   

Abstract

Emerging evidences have indicated that long non-coding RNAs (LncRNAs) play vital roles in cancer development and progression. Previous studies have suggested that overexpression of SPRY4-IT1 predicates poor prognosis and promotes tumor progress in several cancers. However, the underlying mechanism of SPRY4-IT1 in bladder cancer remains unknown. In this study, we found that SPRY4-IT1 knockdown induced inhibition of cell proliferation, cell migration and invasion ability, and caused promotion of apoptosis in bladder cancer both in vitro and in vivo. Mechanistically, knockdown of SPRY4-IT1 increased the expression of miR-101-3p and subsequently inhibited the expression of EZH2 at posttranscriptional level. Importantly, SPRY4-IT1 could directly interact with miR-101-3p and down-regulation of miR-101-3p efficiently reversed the suppression of EZH2 induced by SPRY4-IT1 shRNA. Thus, SPRY4-IT1 positively regulated the expression of EZH2 through sponging miR-101-3p, and played an oncogenic role in bladder cancer progression. Together, our study elucidates the role of LncRNA SPRY4-IT1 as a miRNA sponge in bladder cancer, and sheds new light on LncRNA-directed diagnostics and therapeutics in bladder cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; EZH2; Long noncoding RNA; SPRY4-IT1; miR-101-3p

Mesh:

Substances:

Year:  2016        PMID: 27998761     DOI: 10.1016/j.canlet.2016.12.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  89 in total

1.  [Construction of prognostic model and identification of prognostic biomarkers based on the expression of long non-coding RNA in bladder cancer via bioinformatics].

Authors:  F L Yang; K Hong; G J Zhao; C Liu; Y M Song; L L Ma
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

Review 2.  MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases.

Authors:  Irene Faravelli; Stefania Corti
Journal:  Mol Neurobiol       Date:  2017-06-29       Impact factor: 5.590

3.  Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer.

Authors:  Shuping Xie; Quanxing Ge; Xueyan Wang; Xinfang Sun; Yuhua Kang
Journal:  Cell Cycle       Date:  2018-01-17       Impact factor: 4.534

4.  LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis.

Authors:  Kun-Peng Zhu; Xiao-Long Ma; Chun-Lin Zhang
Journal:  Mol Ther       Date:  2017-07-05       Impact factor: 11.454

5.  lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27.

Authors:  Zhipeng Ma; Senyao Xue; Bi Zeng; Daoxian Qiu
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

6.  Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Ang Zheng; Lin Zhang; Xinyue Song; Feng Jin
Journal:  Histol Histopathol       Date:  2019-10-22       Impact factor: 2.303

7.  Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.

Authors:  Na Shao; Liang Song; Xiaogang Sun
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

Review 8.  Diagnostic, prognostic and therapeutic potential of long noncoding RNAs in cancer.

Authors:  Muhammad Babar Khawar; Syeda Eisha Hamid; Tayyba Jan; Muddasir Hassan Abbasi; Muhammad Idnan; Nadeem Sheikh
Journal:  Mol Biol Rep       Date:  2022-01-24       Impact factor: 2.316

9.  LncRNA ZNF503-AS1 acts as a tumor suppressor in bladder cancer by up-regulating Ca2+ concentration via transcription factor GATA6.

Authors:  Haiqing He; Shuiqing Wu; Kai Ai; Ran Xu; Zhaohui Zhong; Yinhuai Wang; Lei Zhang; Xiaokun Zhao; Xuan Zhu
Journal:  Cell Oncol (Dordr)       Date:  2020-10-01       Impact factor: 6.730

Review 10.  miRNAs as Potential Treatment Targets and Treatment Options in Cancer.

Authors:  Nina Petrovic; Sercan Ergun
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.